ERGOMED PLC LS -,01 WKN: A117XM ISIN: GB00BN7ZCY67 Kürzel: 2EM Forum: Aktien Thema: Hauptdiskussion

Momentum continues with EBITDA upgrades https://www.edisongroup.com/publication/momentum-continues-with-ebitda-upgrades/29809

High sales in H1 2021 and excellent forward visibility Further strategic progress https://www.ergomedplc.com/ergomed-h1-2021-trading-update/

Ergomed plc - Trading Update +Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*) +CRO division delivered strong growth with revenue up 90.7% over H1 2020 to £27.2 million, including the MedSource business acquired in 2020, with like-for-like growth of 16.1% (24.5% in constant currency) https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/1010148

FY21e EBITDA ‘materially ahead’ of consensus https://www.edisongroup.com/publication/fy21e-ebitda-materially-ahead-of-consensus/29610

M&A remains on the agenda with plenty of firepower https://www.edisongroup.com/publication/whats-next-after-stellar-2020-performance/29566

European Mediscience Awards 2021 1. Ergomed has been shortlisted for “Best Communication Award” and “Company of the Year”. http://www.mediscience-event.co.uk/nominations-overview/

https://www.ergomedplc.com/mark-enyedy-appointed-to-board-as-non-executive-director/

Mark Enyedy Appointed to Board as Non-Executive Director Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally. Prior to ImmunoGen, Mr Enyedy served in various executive capacities at Shire plc, including as Executive Vice President and Head of Corporate Development, a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at Genzyme Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions. https://www.investegate.co.uk/ergomed-plc--ergo-/rns/board-changes/202105100700089974X/

Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases. He has extensive experience of public and private financings, M&A, the formation of strategic partnerships and numerous transactions in the CRO, biotech and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches and the eventual sale of the Company to Horizon Pharmaceuticals in 2016. He was also a member of the Board of Mannkind Corporation through its successful Nasdaq listing, and Immunovaccine Inc. through several successful fundraises. https://www.investegate.co.uk/ergomed-plc--ergo-/rns/board-changes/202104290700119928W/

Ergomed opens PrimeVigilance business in Japan The Japanese pharmaceutical market is the fourth-largest in the world after the US, the EU and China “With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region. “Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist." https://www.proactiveinvestors.co.uk/companies/news/947566/ergomed-opens-primevigilance-business-in-japan-947566.html

Eine Perle die jeder im Depot haben sollte

Dito. War 2G Energy wohl die falsche Entscheidung.

Schade zu spät, das wäre was gewesen;(

News Flow stimmt. Würde jetzt gerne nochmal zu 1,4 reinkommen. Bleibt auf jedenfall auf der Watchliste.

Irgendwann kann hier die Trendwende kommen

Kurs 1.4